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Inhibition of Transcription Factor Specificity
Protein 1 Alters the Gene Expression Profile of
Keratinocytes Leading to Upregulation of
Kallikrein-Related Peptidases and Thymic Stromal
Lymphopoietin
Lianghua Bin1, Byung E. Kim1, Clifton F. Hall1, Sonia M. Leach2 and Donald Y.M. Leung1,3
Transcription factor specificity protein 1 (Sp1) is involved in diverse cellular functions. We recently found that
Sp1 was significantly decreased in skin biopsy samples obtained from patients with atopic dermatitis (AD) and
had an even greater reduction in AD patients with a history of eczema herpeticum. In the current study, we
sought to better understand the role of Sp1 in skin biological processes by using a small-interfering RNA
(siRNA) technique to knock down Sp1 gene expression in normal human keratinocytes (NHKs) and investigated
the genome-wide gene expression profiling of Sp1-silenced NHKs. The gene arrays revealed that 53 genes had
greater than 3-fold changes in the expression in Sp1-silenced NHKs as compared with scrambled siRNA-silenced
cells. Strikingly, six kallikrein (KLK)-related peptidase genes, namely KLK5, KLK6, KLK7, KLK8, KLK10, and KLK12,
were upregulated in NHKs following Sp1 silencing. Functionally, protease activity was significantly enhanced
in Sp1-silenced keratinocytes as compared with scrambled siRNA-silenced keratinocytes. Moreover, thymic
stromal lymphopoietin (TSLP), an epithelial-derived TH2-promoting cytokine, was induced in Sp1-silenced
keratinocytes because of elevated KLK activity. These results indicate that Sp1 expression deficiency leads to
abnormally increased KLK protease activity in keratinocytes and may contribute to TH2 immune responses in the
skin by inducing TSLP.
Journal of Investigative Dermatology (2011) 131, 2213–2222; doi:10.1038/jid.2011.202; published online 14 July 2011
INTRODUCTION
Sp1 is a transcription factor that belongs to the SP/XKLF
(specificity protein/Kruppel-like factor) family. Its DNA-bind-
ing domain possesses three C2H2-type zinc fingers that have
higher binding affinities to GC boxes and lower binding
affinities to CT and GT boxes (Wierstra, 2008). Aside from
regulating gene expression by binding to its own binding sites,
Sp1 appears as a versatile partner for many other transcrip-
tion factors in activating or repressing its responsive genes.
Sp1 was originally characterized as a transcription factor
for constitutive activation of housekeeping genes. More
recently, it has become clear that Sp1 also possesses
regulatory function and is actively involved in tissue-specific
gene expression and responses to induced signals (Hu et al.,
2007; Wu et al., 2009). Although Sp1 gene expression is
ubiquitous, several studies have shown that its expression
varies substantially in different cell types or in the same cell
type at different stages of development (Saffer et al., 1991).
The human kallikrein (KLK)-related peptidase family
comprises 15 secreted serine proteases (KLK1–KLK15) that
possess trypsin- or chymotrypsin-like enzyme activities
(Yousef and Diamandis, 2001). To date, eight KLK proteins,
namely KLK5, KLK6, KLK7, KLK8, KLK10, KLK11, KLK13,
and KLK14, have been found in stratum corneum tissues and
skin appendages (Komatsu et al., 2005, 2006). The KLK
function has been proposed as desquamatory enzymes by
causing degradation of corneodesmosomal adhesion proteins
in the stratum corneum and leading to shedding of the
outmost layer of the skin (Borgono et al., 2007; Eissa and
Diamandis, 2008; Eissa et al., 2011). KLKs’ protease activity
and their corresponding inhibitors are strictly regulated under
physiological conditions (Cork et al., 2009). Elevated KLK
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gene expressions have been found in skin diseases with skin
barrier disorders, such as psoriasis (Komatsu et al., 2007a),
acne rosacea (Yamasaki et al., 2007), and atopic dermatitis
(AD) (Komatsu et al., 2007b).
Human thymic stromal lymphopoietin (TSLP) is a cytokine
mainly expressed by atopic epithelial cells such as keratinocytes
(Reche et al., 2001). Human dendritic cells, stimulated by TSLP,
produce chemokines that attract TH2-type CD4
þ T cells; and
TSLP-treated dendritic cells drive CD4þ T cells to differentiate
into a TH2 phenotype producing IL4, IL5, and IL13 (Reche et al.,
2001; Soumelis et al., 2002). The discovery that TSLP promotes
TH2 immune responses inspired new insights into the important
role of the epithelium in initiating and controlling immune
responses. Indeed, TSLP expression has been significantly
elevated in the epidermis from patients with AD and Nether-
ton’s syndrome (NS), a disease with severe AD-like skin
manifestations (Soumelis et al., 2002; Briot et al., 2009).
Interestingly, Briot et al. (2009) found that unstrained KLK5 in
NS patients was responsible for elevated TSLP expression.
Recently, we found that inhibition of Sp1 gene expression
enhanced vaccinia virus and herpes simplex virus replication
in keratinocytes by attenuating the anti-viral innate immune
response (Bin et al., 2011). Furthermore, we found that Sp1
gene expression was significantly decreased in skin biopsy
samples obtained from patients of AD. Interestingly, AD
patients with a history of eczema herpeticum (ADEH) had
significantly lower levels of Sp1 than did those without a
history of viral infection. AD is a chronic inflammatory skin
disease, which is characterized by elevated TH2 infiltration
and loss of skin barrier function (Cork et al., 2009;
Boguniewicz and Leung, 2010). ADEH subjects have more
severe eczema and increased TH2 responses than do regular
AD (Beck et al., 2009). The findings of Sp1 deficiency in AD
and ADEH prompted us to further investigate the role of Sp1 in
keratinocytes’ biological processes. In this study, we reported
that Sp1 silencing changed the expression profile of keratino-
cytes and led to the upregulation of six KLK family members.
The elevated gene expression of KLKs resulted in significantly
enhanced protease activity and augmentation of TSLP levels in
Sp1-silenced cells. The current study indicates that epidermal
Sp1 deficiency may contribute to TH2 immune responses in
the skin by enhancing the expression of TSLP in keratinocytes.
RESULTS
Inhibition of Sp1 alters gene expression profiling of
keratinocytes
To gain better insights into the molecular perturbations
induced by reduced Sp1 expression in keratinocytes, we used
a gene microarray approach to identify genes that were
affected by the downregulation of Sp1. Normal human
keratinocytes (NHKs) were transfected with small-interfering
RNA (siRNA) duplexes specifically targeting Sp1 or control-
scrambled siRNA. Sp1 mRNA levels and proteins levels in
NHKs were monitored up to 4 days after transfection of
siRNA duplexes. As shown in Supplementary Figure S1
online, both Sp1 mRNA and protein were decreased in NHKs
following transfection of Sp1 siRNA duplexes at day 1 and
this difference persisted for 4 days. Transfection with control-
scrambled siRNA did not affect Sp1 expression. RNA
extracted from NHKs after 72 hours of transfection with
siRNA duplexes was used for gene profiling studies. Three
independent experiments were performed and analyzed
using Affymetrix GeneChip Human Genome U133 plus 2.0
arrays. Sp1 downregulation was associated with a substantial
modification of gene transcription profiles. Using scrambled
siRNA-transfected cells as the reference, we found 1,268
genes with unique gene symbol identifiers to be differentially
expressed with 41.5-fold change. The expression of 576
genes was increased, whereas that of 692 genes was decreased.
With a 3-fold change of expression, 53 genes with unique gene
symbol identifiers were found differentially expressed with 27
upregulated and 26 downregulated genes. Table 1 shows the
most upregulated and downregulated genes. Sp1 inhibition
had an effect on the expression of many genes involved in
multiple cellular functions, including metabolism, inflamma-
tion, proliferation, and apoptosis, etc.
Among the top four most upregulated genes associated
with Sp1 silencing, S100A12 is known to be a proinflamma-
tory protein that possesses chemotactic activity for monocytes
and mast cells (Yan et al., 2008); KLK-related peptidase 6
(KLK6) is a serine protease involved in the process of
desquamation (Borgono et al., 2007); VNN3 (vanin 3) is a
protein belonging to the pantetheinase enzyme family that
catalyzes the conversion of vitamin B5 into the antioxidant
cysteamine (Martin et al., 2001, 2004). Expressions of these
three genes have been previously reported to be increased in
the skin of AD patients and other allergic diseases (Komatsu
et al., 2007b; Yang et al., 2007; Jansen et al., 2009). Using
real-time PCR in NHK cells from three different donors and
three different Sp1 siRNA duplexes, we confirmed that the
gene expression of these three genes are indeed upregulated
in Sp1-silenced NHK cells as compared with cells transfected
with scrambled siRNA duplexes (Figure 1).
Keratin 13 (KRT13) and keratin 19 (KRT19) are the top two
most downregulated genes in Sp1-silenced NHKs, and
keratin 15 (KRT15) was also downregulated 3.8-fold follow-
ing Sp1 silencing. Both KRT19 and KRT15 are biomarkers for
skin stem cells (Pontiggia et al., 2009), whereas mutations in
KRT13 result in white sponge naevus (OMIM 193900)
(Shibuya et al., 2003). We confirmed that these three genes
were downregulated in Sp1-silenced NHK cells by real-time
PCR in NHKs from three different donors (Figure 1).
KLK family members are upregulated in Sp1-silenced
keratinocytes
Several lines of evidence have implicated KLK family members
in the pathogenesis of TH2-mediated skin diseases including
AD and NS, a rare genetic skin disease with AD-like skin
manifestations (Bitoun et al., 2002; Komatsu et al., 2006,
2007b). Therefore, we searched further for KLK family members
with expression changes following Sp1 silencing in NHK cells.
We were struck by the finding that 10 probes representing
6 KLK family members were upregulated in Sp1-silenced
NHK cells analyzed by gene profiling. As shown in Table 2,
KLK6, KLK10, KLK12, KLK8, KLK5, and KLK7 were upregulated
to different degrees from 1.45- to 5.27-fold.
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Table 1. Genes affected by Sp1 silencing
Relative intensity (mean±SEM)
Affymetrix ID Symbol Full name Scrambled siRNA Sp1 siRNA Fold change P-value
Metabolism
212816_s_at CBS Cystathionine-b-synthase 76.97±17.94 463.1±169.8 6.02 NS
206643_at HAL Histidine ammonia-lysase 539.4±20.38 2521±140.2 4.67 **
206177_s_at ARG1 Arginase, liver 646.5±55.23 2667±348.5 4.12 *
217127_at CTH Cystathionase (cystathionine g-lyase) 286.7±82.59 1056±172.6 3.68 NS
211788_s_at TREX Three prime repair exonuclease 2 155.4±11.99 564.2±31.81 3.63 ***
231202_at ALDH1L2 Aldehyde dehydrogenase 1 family, member L2 21.67±4.486 85.3±28.12 3.94 NS
203438_at STC2 Stanniocalcin 2 214.9±67.02 670.8±124.8 3.12 *
205047_s_at ASNS Asparagine synthetase 873.8±224.7 2999±825.5 3.43 NS
238029_s_at SLC16A14 Solute carrier family 16, member 14 (monocarboxylic acid
transporter 14)
10.53±1.364 34.97±3.597 3.32 **
208126_s_at CYP2C18 Cytochrome P450, family 2, subfamily C, polypeptide 18 71.33±2.483 218.3±15.59 3.06 ***
224009_x_at DHRS9 Dehydrogenase/reductase (SDR family) member 9 390.6±16.85 1213±197.8 3.10 *
208998_at UCP2 Uncoupling protein 2 (mitochondrial, proton carrier) 955.4±2.776 196.9±17.97 4.85 ***
223044_at SLC40A1 Solute carrier family 40 (iron-regulated transporter), member 1 232.0±7.365 54.43±9.879 4.26 ***
210519_s_at NQO1 NAD(P)H dehydrogenase, quinine 1 1724±32.77 501.5±44.00 3.43 **
206561_s_at AKR1B10 Aldo-keto reductase family 1, member B10 (aldose reductase) 563.5±35.33 171.3±18.33 3.29 ***
201042_at TGM2 Transglutaminase 2(C polypeptide, protein-glutamine-g-
glutamyltransferase)
296.4±21.87 92.30±13.51 3.21 ***
Cell growth and apoptosis
215785_s_at CYFIP2 Cytoplasmic FMR1-interacting protein 2 71.40±3.544 275.6±22.37 3.85 ***
226492_at SEMA6D Sema domain, transmembrane domain (TM), and cytoplasmic
domain, (semaphorin) 6D
49.83±5.912 13.20±1.464 3.77 **
202409_at IGF2///INS-IGF2 Insulin-like growth factor 2 (somatomedin A)///INS-IGF2
readthrough transcript
2082±37.40 597.7±37.49 3.48 ***
211959_at IGFBP5 Insulin-like growth factor-binding protein 5 98.93±15.52 29.27±4.53 3.38 *
1552701_a_at CARD16 Caspase recruitment domain family, member 16 320.9±26.74 89.83±8.07 3.57 **
205081_at CRIP1 Cysteine-rich protein 1 (intestinal) 164.0±9.40 47.57±0.38 3.44 ***
Transcription factor
236265_at SP4 Sp4 transcription factor 135.3±9.734 517.3±57.95 3.82 **
Inflammation
205863_at S100A12 S100 calcium-binding protein A12 101.8±5.4 690.6±9.04 6.78 ***
220528_at VNN3 Vanin 3 27.00±0.51 152.3±15.09 5.64 **
Receptor and transmembrane protein
204007_at FCGR3B Fc fragment of IgG, low-affinity IIIb, receptor (CD16b) 36.37±4.70 242.0±42.53 6.65 **
221107_at CHRNA9 Cholinergic receptor, nicotinic, a-9 44.60±0.70 190.7±33.45 4.27
228176_at SIPR3 Sphingosine-1-phosphate receptor 3 101.8±9.18 24.30±3.24 4.19 **
Mucus secretion
209173_at AGR2 Anterior gradient homolog 2 (Xenopus laevis) 321.4±11.59 106.7±8.23 3.01 ***
Table 1 continued on the following page
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We investigated the dynamic gene expression of KLK
family members up to 4 days following Sp1 silencing. As
shown in Figure 2, KLK5, KLK6, KLK7, and KLK12 were
increased in expression 2 days after transfection of Sp1
siRNA, whereas KLK8 and KLK10 were upregulated 1 day
after transfection of Sp1 siRNA. However, the greatest
increase of all six genes as compared with controls was at
3 days after transfection. We also harvested protein lysates
Table 1. Continued
Relative intensity (mean±SEM)
Affymetrix ID Symbol Full name Scrambled siRNA Sp1 siRNA Fold change P-value
Membrane protein
219313_at GRAMDIC GRAM domain containing 1C 43.00±0.15 146.1±20.22 3.40 **
229927_at LEMD1 LEM domain containing 1 129.2±10.31 26.07±1.24 4.96 ***
232176_at SLITRK6 SLIT and NTRK-like family, member 6 134.8±5.48 35.00±8.96 3.85 ***
228080_at LAYN Layilin 184.9±3.89 53.13±4.30 3.48 ***
214297_at CSPG4 Chondroitin sulfate proteoglycan 4 182.0±6.53 55.67±12.32 3.27 ***
220090_at CRNN Cornulin 98.43±9.19 31.30±2.89 3.14 **
Epidermis development/intermediate filament
207935_s_at KRT13 Keratin 13 4027±154.0 515.7±108.7 7.81 ***
201650_at KRT19 Keratin 19 2149±163.7 309.4±88.33 6.95 ***
204734_at KRT15 Keratin 15 3911±155.2 1067±230.4 3.66 ***
Extracellular matrix
206101_at ECM2 Extracellular matrix protein 2, female organ and adipocyte
specific
56.73±12.23 253.9±71.26 4.48 NS
208978_at CRIP2 Cysteine-rich protein 2 1431±52.16 455.8±65.88 3.14 ***
211964_at COL4A2 Collagen, type IV, a2 360.7±18.67 111.2±7.16 3.24 ***
Wnt signaling pathway
202036_s_at SFRP1 Secreted frizzled-related protein 1 178.8±44.04 55.97±6.56 3.20 NS
Serine protease
204733_at KLK6 Kallikrein-related peptidase 6 80.87±2.30 463.1±39.02 5.72 ***
Protease inhibitor
202833_s_at SERPINA1 Serpin peptidase inhibitor, clade A (a-1 antiproteinase,
antitrypsin), member 1
68.03±1.62 18.37±0.86 3.70 ***
Unknown function
1558212_at FLI35024 Hypothetical LOC401491 27.97±2.97 118.4±31.6 4.23 *
227410_at FAM43A Family with sequence similarity 43, member A 172.0±10.24 650.7±70.41 3.78 **
230765_at KIAA1239 KIAA1239 32.63±2.85 117.5±16.24 3.60 NS
226905_at FAM101B Family with sequence similarity 101, member B 187.2±17.27 638.0±65.02 3.41 *
232689_at LOC284561 Hypothetical protein LOC284561 31.10±4.82 112.7±31.41 3.62 ***
1558195_at LOC283404 Hypothetical protein LOC283404 121.2±9.83 402.8±65.64 3.32 **
226723_at CCDC23 Coiled-coil domain containing 23 299.3±9.36 908.3±69.25 3.03 **
218723_s_at C13orf15 Chromosome 13 open reading frame 15 187.6±19.75 32.73±5.55 5.73 **
236984_at C4orf26 Chromosome 4 open reading frame 26 32.20±1.79 10.63±1.22 3.03 **
Abbreviations: ANOVA, analysis of variance; NHK, normal human keratinocyte; siRNA, small-interfering RNA; Sp1, specificity protein 1.
Genes identified by microarray analysis (Affymetrix GeneChip Human Genome U133 plus 2.0) have greater than 3-fold of upregulation or downregulation
following Sp1 silencing in NHK (three independent experiments). Differential gene expression following Sp1 silencing relative to control was determined by
GeneSpring GX 7.3 statistical analysis module ANOVA and t-test.
*Po0.05; **Po0.01; ***Po0.001.
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from cells after 3 days of silencing Sp1 and confirmed that six
kinds of KLK protein levels were increased in Sp1-silenced
NHK cells (Supplementary Figure S2 online).
Protease activity is enhanced in Sp1-silenced keratinocytes but
does not affect skin barrier protein FLG protein level
The KLK proteins are secreted proteins and possess trypsin-
and chymotrypsin-like activities (Yousef and Diamandis,
2001). Therefore, we investigated whether upregulation of
KLKs in Sp1-silenced NHKs led to enhanced protease activity.
As shown in Figure 3a, the functional protease activity in cell
culture supernatants from Sp1-silenced NHK cells was
significantly increased as compared with scrambled siRNA-
silenced NHK cells.
Previous studies have reported that human KLK5 and KLK7
degraded corneodesmosome components, desmoglein 1,
desmocollin 1, and corneodesmosin, by in vitro proteolysis
assay (Simon et al., 2001; Caubet et al., 2004). However, we
did not detect degradation of these proteins in Sp1-silenced
NHK cells (data not shown). We then investigated whether
skin barrier protein filaggrin (FLG) protein level was
decreased in Sp1-silenced NHK cells after 5 days of Ca2þ -
driven differentiation. As shown in Figure 3b, both pro-FLG
and monomer FLG were not decreased in Sp1-silenced NHK
cells as compared with cells transfected with scrambled
siRNA. On the contrary, FLG protein level was increased in
Sp1-silenced NHKs as compared with cells transfected with
scrambled siRNA. However, if Sp1-silenced NHKs were
0.008 0.010 0.020
Vanin 3
**
**
**
0.015
0.010
0.005
0.000
0.060.0080.25
0.20
0.15
0.10
0.05
0.00
0.006
0.004
0.002
0.000
Keratin 15Keratin 13Keratin 19
**
*****
**
**
*** ***
**
**
0.04
0.02
0.00
S100A12
**
*
***
0.008
0.006
0.004
0.002
0.000
Kallikrein-related peptidase 6
0.006
0.004
R
el
at
ive
 g
en
e
ex
pr
es
sio
n/
18
S
R
el
at
ive
 g
en
e
ex
pr
es
sio
n/
18
S
R
el
at
ive
 g
en
e
ex
pr
es
sio
n/
18
S
R
el
at
ive
 g
en
e
ex
pr
es
sio
n/
18
S
R
el
at
ive
 g
en
e
ex
pr
es
sio
n/
18
S
R
el
at
ive
 g
en
e
ex
pr
es
sio
n/
18
S
0.002
0.000
No.1 No.1No.2 No.2No.3 No.3
Sp1 siRNA Sp1 siRNA
**
*
***
Scrambled
siRNA
Scrambled
siRNA
No.1 No.2 No.3
Sp1 siRNA
Scrambled
siRNA
No.1 No.2 No.3
Sp1 siRNA
Scrambled
siRNA
No.1 No.2 No.3
Sp1 siRNA
Scrambled
siRNA
No.1 No.2 No.3
Sp1 siRNA
Scrambled
siRNA
Figure 1. Confirmation of differentially expressed genes revealed by gene profiling. NHK cells were transfected with scrambled siRNA duplexes and
three different Sp1 siRNA duplexes for 3 days. mRNA levels of KLK6, S100A12, VNN3, KRT19, KRT13, and KRT15 were measured by quantitative
real-time PCR. Data are shown as mean±SEM. Results are representative of three experiments. *Po0.05; **Po0.01; ***Po0.001. KLK, kallikrein;
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Table 2. KLK family members are upregulated in Sp1-silenced keratinocytes
Relative intensity (mean±SEM)
Probe set Gene name Scrambled siRNA Sp1 siRNA Ratio (Sp1 siRNA/scrambled siRNA P-value
204733_at KLK6 88.88±4.02 425.95±67.56 5.27 ***
215808_at KLK10 53.46±6.04 187.17±69.40 3.5 *
220782_x_at KLK12 85.39±7.17 233.29±13.00 2.73 ***
233687_s_at KLK8///KLK9 47.97±8.30 112.87±6.54 2.35 ***
234316_x_at KLK12 96.42±7.28 219.07±32.08 2.27 **
209792_s_at KLK10 3541.23±320.10 6723.03±415.80 1.9 ***
1552319_a_at KLK8 219.66±5.91 363.16±22.27 1.65 ***
222242_s_at KLK5 4633.18±599.77 7657.66±160.40 1.65 **
205778_at KLK7 3077.18±306.69 4459.33±759.10 1.45 *
239381_at KLK7 2275.83±72.40 3542.96±102.97 1.56 ***
Abbreviations: KLK, kallikrein; siRNA, small-interfering RNA; Sp1, specificity protein 1.
Genes identified by microarray analysis (Affymetrix GeneChip Human Genome U133 plus 2.0).
*Po0.05; **Po0.01; ***Po0.001.
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differentiated in the presence of TH2 cytokines (IL4/IL13),
FLG protein expression levels were suppressed.
TSLP gene expression is upregulated in Sp1-silenced NHKs
depending on KLKs’ protease activity
TSLP is believed to have a central role in atopic inflammatory
diseases and it has been found to be induced by KLK5
(Soumelis et al., 2002; Ebner et al., 2007; Briot et al., 2009).
As multiple KLK proteins were upregulated and protease
activity was enhanced in Sp1-silenced keratinocytes, we
were interested in whether TSLP was upregulated in Sp1-
silenced keratinocytes. We first searched for TSLP expression
in our gene array data, and found that its expression was
increased in Sp1-silenced NHKs by 2.7-fold as compared
with controls. We further confirmed TSLP gene expression at
both the mRNA and the protein levels. As shown in Figure 4a,
TSLP mRNA was significantly increased at days 3 and 4
following Sp1 silencing as compared with scrambled
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FLG, filaggrin; NHK, normal human keratinocyte; siRNA, small-interfering RNA; Sp1, specificity protein 1.
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siRNA-transfected keratinocytes. We harvested protein from
cells after 4 days of transfection with Sp1 siRNA duplexes and
found that the TSLP protein was increased in Sp1-silenced
keratinocytes detected by western blot (Figure 4b).
As upregulation of TSLP followed KLKs’ upregulation as
indicated by our time course study, we determined whether
TSLP upregulation in Sp1-silenced NHK cells was a response
to increased KLK activity. To test this hypothesis, we used a
serine protease inhibitor, 4-(2-aminoethyl) benzenesulfonyl
fluoride hydrochloride (AEBSF), to inhibit protease activity in
Sp1-silenced NHKs. As shown in Figure 4c, TSLP upregula-
tion was significantly inhibited in Sp1-silenced NHK cells
along with increased concentration of AEBSF. To further
define whether TSLP upregulation is a secondary response to
increased KLK production, we used neutralizing antibodies to
block the effects of the six upregulated KLKs in Sp1-silenced
NHKs. As shown in Figure 4d, TSLP was not upregulated in
Sp1-silenced NHK cells in the presence of KLK-neutralizing
antibodies. Thus, TSLP upregulation in Sp1-silenced NHKs
was dependent on augmented KLK protease activity.
DISCUSSION
The goal of the current study was to advance our under-
standing of the biological consequence of keratinocyte
deficiency of Sp1 expression. In this paper, we demonstrated
that six KLK family members, namely KLK5, KLK6, KLK7,
KLK8, KLK10, and KLK12, were significantly increased in
Sp1-silenced keratinocytes. The functional significance of our
gene expression data was supported by the observation of
enhanced functional protease activity. TSLP gene expression
was also significantly augmented in Sp1-silenced NHKs. As
growing evidence has shown that enhanced protease activity
in the epidermis is detrimental to skin barrier function and
TSLP orchestrates allergic inflammation (Descargues et al.,
2005; Hachem et al., 2006; Elias et al., 2008; Ziegler, 2010),
our findings suggest that Sp1 epidermal deficiency may have
a role in allergic skin diseases, such as AD and ADEH.
Among the KLKs expressed in the skin, only KLK5 (a tryptic
enzyme) and KLK7 (a chymotryptic enzyme) have been
studied in great detail in terms of their enzymatic activities
and substrates (Cork et al., 2009). In vitro experiments have
shown that KLK5 and KLK7 can degrade desmosomal
adhesion proteins including desmoglein 1, corneodesmosin,
and desmocollin 1 (Caubet et al., 2004). Their enzymatic
activities can be affected by pH and the presence of serine
protease inhibitors (Deraison et al., 2007). Of note, seven
KLKs proteins, including KLK5, KLK6, KLK7, KLK8, KLK10,
KLK13, and KLK14, have been found to be elevated in the
stratum corneum of patients with AD (Komatsu et al., 2007b).
However, the mechanism by which KLKs are upregulated in
AD is incompletely understood. Mutations in the serine
protease inhibitor Kazal-type 5 (SPINK5) gene has been
reported in patients with NS (Chavanas et al., 2000;
Bitoun et al., 2002). SPINK5 encodes the protein of the
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Figure 4. TSLP gene expression is upregulated in Sp1-silenced NHKs depending on enhanced protease activity. (a) TSLP mRNA is significantly increased at
days 3 and 4 following Sp1 silencing as compared with NHKs transfected with scrambled siRNA. (b) TSLP protein was detected by western blot in NHKs 4 days
after transfection of siRNA duplexes. (c) NHK cells were transfected with scrambled siRNA and Sp1 siRNA duplexes in the absence and presence of protease
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lymphoepithelial Kazal-type 5 serine protease inhibitor,
which is a specific inhibitor of KLK5, KLK7, and KLK14.
Briot et al. (2009) have recently demonstrated that hyper-
activity of KLK5 in lymphoepithelial Kazal-type 5 serine
protease inhibitor-deficient keratinocytes of patients with NS
has a key role in causing atopic skin lesions, thus highlighting
the clinical significance of enhanced epidermal serine
protease activity in the pathogenesis of NS. The reports of
SPINK5 mutations in NS have attracted several groups to
investigate the association of SPINK5 gene variants in AD
(Walley et al., 2001; Kato et al., 2003; Nishio et al., 2003;
Kabesch et al., 2004; Moffatt, 2004; Folster-Holst et al., 2005;
Jongepier et al., 2005; Hubiche et al., 2007). However, their
results were contradictory, suggesting that SPINK5 genetic
variants only partially account for genetic predisposition to
AD. We propose that epidermal deficiency of Sp1 in AD and
ADEH may be an additional mechanism leading to elevated
KLKs in patients with AD.
Our data also support the finding of Broit et al. that
increased serine protease activity significantly augments TSLP
gene expression in keratinocytes. This is an important
confirmatory finding as TSLP is a critical cytokine that
promotes TH2 cell development in the pathogenesis of AD
(Ziegler, 2010). TSLP-treated dendritic cells induce naive
CD4þ T cells to undergo proliferation and differentiation into
TH2 lymphocytes, leading to enhanced production of IL4,
IL5, and IL13 (Soumelis et al., 2002). Transgenic mice
overexpressing TSLP specifically in keratinocytes develop
spontaneous AD disease (Yoo et al., 2005). TSLP gene
expression is elevated in the epidermis of patients with AD
and NS (Soumelis et al., 2002; Briot et al., 2009).
Aside from KLKs and TSLP, several other genes that are
differentially expressed in Sp1-silenced NHKs have also been
implicated in the pathogenesis of AD. In this study, it was
found that S100A12, a chemoattractant for monocytes and
mast cells (Yan et al., 2008), is the most upregulated gene
following Sp1 silencing. Of interest, a recent study demon-
strated that S100A12 induces degranulation of mast cells and
amplifies IgE-mediated responses, implicating its involvement
in allergic inflammatory response (Yang et al., 2007). VNN3,
another gene that we found is also greatly upregulated
following Sp1 silencing, has been reported to be significantly
increased in AD skin lesions (Jansen et al., 2009). However,
the biological function of VNN3 in the skin is still not clear.
Our gene array data in Table 1 also showed downregulation
of CRNN (Cornulin) in Sp1-silenced HNK. As the CRNN gene
is located in the epidermal differentiation complex gene
cluster and its protein is found mainly in the granular layer of
the epidermis (Contzler et al., 2005), it is considered to be a
marker of late epidermal differentiation. CRNN is signifi-
cantly downregulated in the skin of patients with AD (Lieden
et al., 2009).
Taken together, reduced Sp1 leads to a unique pattern of
altered gene expression, which mimics some of the dysregu-
latory features of the AD skin. Importantly, we have
demonstrated that Sp1 deficiency leads to enhanced protease
activity and overproduction of the major pro-TH2 cytokine,
TSLP, in keratinocytes; to our knowledge this is previously
unreported. Although we did not detect the degradation of
desmoglein 1, desmocollin 1, corneodesmosin, and FLG in
Sp1-silenced NHKs, we showed that TH2 cytokines treatment
can suppress FLG protein expression in Sp1-silenced NHKs.
These results suggest that Sp1 deficiency in the skin of
patients with AD and ADEH may contribute to the
pathogenesis of these complex skin diseases by inducing
TSLP, which in turn promotes the elevation of TH2 cytokines.
MATERIALS AND METHODS
Keratinocyte culture
The NHKs were purchased from Cascade Biologics/Invitrogen
(Portland, OR) and maintained in serum-free EpiLife medium
containing 0.06mM CaCl2 and S7 supplemental reagent (Cascade
Biologics/Invitrogen) under standard tissue culture conditions.
siRNAs silencing experiment and serine protease inhibitor
treatment
Sp1 and silencer negative control 1 siRNA duplexes were purchased
from Ambion (Austin, TX). Sequences for targeting Sp1were as
follows: Sp1 no. 1 siRNA: 50-GCAACAUGGGAAUUAUGAA-30; Sp1
no. 2 siRNA: 50-GGCAGACCUUUACAACUCA-30; Sp1 no. 3 siRNA:
50-CCACAAGCCCAAACAAUCA-30. NHK cells were plated in 24-
well plates at 1 105 per well the day before transfection. Cells were
transfected with siRNA duplexes at a final concentration of 10 nM
using lipofectamine 2000 according to the manufacturer’s instruc-
tions (Invitrogen, Carlsbad, CA). Sp1 no. 1 siRNA was used if there
was no indication. Serine protease inhibitor, AEBSF, was purchased
from Sigma-Aldrich (St Louis, MO). AEBSF (6-20 mM) was added to
NHK cells after overnight incubation with Sp1 siRNA duplexes, and
then cells were incubated with AEBSF for 2 days. Mouse IgG2A
isotype control, mouse IgG2B isotype control, monoclonal anti-
human KLK5, KLK6, KLK7, KLK8, KLK10, and KLK12 were
purchased from R&D Systems (Minneapolis, MN). In all, 1 mgml1
of each KLK antibody or 5mgml1 of each KLK antibody was added
to Sp1-silenced NHK cells for 3 days, 6 or 30 mgml1 mixed mouse
IgG2A and IgG2B as controls.
RNA isolation and real-time PCR
Total RNA was isolated from cells using RNeasy Mini Kits (Qiagen,
Valencia, CA) according to the manufacturer’s guidelines. RNA was
reverse transcribed into cDNA using superScript III reverse
transcriptase from Invitrogen and analyzed by real-time reverse
transcriptase-PCR using an ABI Prism 7000 sequence detector
(Applied Biosystems, Foster City, CA) as described previously
(Nomura et al., 2003). Primers and probes for human Sp1, KLK5,
KLK6, KLK7, KLK8, KLK10, KLK12, KRT13, KRT15, KRT19, VNN3,
S100A12, TSLP, and 18S were purchased from Applied Biosystems.
Quantities of all target genes in test samples were normalized to the
corresponding 18S levels.
Gene microarray analysis
The microarrays used for this study were Human Genome U133 plus
2.0 arrays (Affymetrix, Santa Clara, CA) containing probe sets of
54,000 transcripts. Total RNA (5 mg) isolated from Sp1-silenced NHK
cells and scrambled siRNA-transfected NHK cells was converted to
double-stranded cDNA and then to biotinylated cRNA. After
fragmentation and quality confirmation, 15 mg of biotinylated cRNA
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was hybridized to microarrays. After washing and staining with
streptavidin–phycoerythrin, the arrays were scanned using a Gene-
array scanner (Hewlett Packard, Palo Alto, CA). Data were analyzed
using Affymetrix Microarray Suite 5.0 software and GeneSpring 10.5
software (Agilent Technologies, Santa Clara, CA).
Western blot
Whole-cell extracts were prepared in the presence of 1% (vol/vol) of
protease inhibitor cocktail and 1% (vol/vol) of phosphatase inhibitor
cocktail (Sigma-Aldrich). Protein was then separated using SDS-
PAGE and then transferred to nitrocellulose membrane (Bio-Rad,
Hercules, CA). The blots were then blocked and incubated with
primary and secondary antibodies. Rabbit anti-human Sp1, rabbit
anti-human TSLP, and rabbit anti-human glyceraldehyde 3-phos-
phate dehydrogenase were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Mouse anti-FLG monoclonal antibody was
purchased from Vector Laboratories (Burlingame, CA) and mouse
anti-b-actin was from Sigma-Aldrich. Blots were developed with ECL
Detection Reagents (GE Healthcare Bio-Sciences, Piscataway, NJ).
Protease activity assay
Protease activity in cell culture supernatants was measured using
EnzChek Protease Assay Kit green fluorescence (Molecular Probes/
Invitrogen) according to the manufacturer’s instructions. In brief, cell
supernatants from HNK cells with treatment of different siRNA
duplexes were mixed with same volume of BODIPY FL casein
substrate in 10mM Tris-HCl, pH 7.8, and incubated at 37 1C for
48 hours. Fluorescence intensity was measured at excitation/emis-
sion of B505/513. Protease activity was determined as increased
fluorescence intensity.
Statistical analysis
All statistical analyses were conducted using GraphPad prism,
version 5.03 (GraphPad, San Diego, CA). Comparisons of expression
levels were performed using analysis of variance techniques and
independent sample t-tests as appropriate. Differences were
considered significant at Po0.05.
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